In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.

Over the last weekend, Chicago played host to the 2026 edition of the Heart Rhythm Society's annual conference (HRS 2026).

A minimally invasive heart procedure may be a better first-line treatment than medication for people living with advanced ...

At the Heart Rhythm Society’s 2026 meeting, Medtronic, Boston Scientific, and Abbott presented encouraging trial data for next‑generation pulsed field ablation (PFA) devices designed to treat ...

At the Heart Rhythm Society’s 2026 meeting, Medtronic, Boston Scientific, Abbott, and others unveiled strong trial results for next-generation arrhythmia treatment devices, particularly pulsed field ...

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large ...

Atraverse was set up by Steven Mickelsen, Eric Sauter and John Slump. Mickelsen and Slump co-founded Farapulse, the pulsed ...

Abbott (NYSE:ABT) today shared new study findings supporting its pulsed field ablation (PFA) and conduction system pacing ...

This article has been written and funded by Boston Scientific. I have worked in cardiology for over 30 years, in hospitals, clinical societies and most recently at Boston Scientific. In that time, I ...

At Johns Hopkins in Baltimore, cardiologists are road-testing a patient-specific "digital twin" of a diseased heart, a computer model used to plan and guide catheter ablation for a dangerous rhythm ...